Initial clinical experience with I.C.I. 66.082, a new beta-adrenergic blocking agent, in hypertension.
D000081:Acetamides / Q000494:pharmacology / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D003864:Depression, Chemical; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010647:Phenyl Ethers / Q000494:pharmacology / Q000627:therapeutic use; D011412:Propanolamines / Q000494:pharmacology / Q000627:therapeutic use*
D000081:Acetamides; D000319:Adrenergic beta-Antagonists; D010647:Phenyl Ethers; D011412:Propanolamines